40 results
8-K
EX-10.1
SLNO
Soleno Therapeutics Inc
29 Sep 23
Entry into a Material Definitive Agreement
4:55pm
by the Securities Act and the Public Company Accounting Oversight Board (United States). Marcum LLP has not been engaged by the Company to perform any
8-K
EX-1.1
SLNO
Soleno Therapeutics Inc
29 Sep 23
Entry into a Material Definitive Agreement
4:55pm
by the Securities Act, the Exchange Act, and the rules of the Public Company Accounting Oversight Board (“PCAOB”), (ii) in compliance with the applicable
424B5
SLNO
Soleno Therapeutics Inc
29 Sep 23
Prospectus supplement for primary offering
4:51pm
requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of noncompliance with these laws
424B5
kk4of5k6
27 Sep 23
Prospectus supplement for primary offering
5:26pm
8-K
EX-10.1
4np3h8vdd1 umav
19 Dec 22
Soleno Therapeutics Announces Financing Commitment for up to $60 Million
4:49pm
8-K
EX-1.1
detej29s46e
16 Jul 21
Entry into a Material Definitive Agreement
4:14pm
8-K
EX-1.1
fhb5u0p6
26 Jun 20
Soleno Therapeutics Announces Pricing of $50 Million Public Offering of Common Stock
4:31pm
424B5
8swbn gdol0a6
25 Oct 19
Prospectus supplement for primary offering
12:00am
424B5
5hsqg4u89 sibk39oqe
22 Oct 19
Prospectus supplement for primary offering
4:24pm